Abbvie lowers annual profit forecast due to $2.7 billion in R&D spending
On October 3rd local time, Abbvie stated in a regulatory filing that it expects to account for related expenses of $2.7 billion for research and development projects in its third-quarter performance. Abbvie indicated that due to this expenditure in the third quarter, the company's adjusted diluted earnings per share for the third quarter will be between $1.74 and $1.78. At the same time, Abbvie has lowered its full-year adjusted diluted earnings per share forecast from the previous estimate of $11.88-12.08 to $10.38-10.58
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments